Hélène Kolesnikov-Gauthier1, Nathalie Lemoine2, Emmanuelle Tresch-Bruneel3, Anaïs Olivier4, Aurore Oudoux4, Nicolas Penel2,5. 1. Department of Nuclear Medicine, Centre Oscar Lambret, 3 rue Frederic Combemale, B.P. 307, 59020, Lille Cedex, France. h-gauthier@o-lambret.fr. 2. Medical Oncology Department, Oscar Lambret Center, Lille, France. 3. Methodology and Biostatistics Unit, Oscar Lambret Center, Lille, France. 4. Department of Nuclear Medicine, Centre Oscar Lambret, 3 rue Frederic Combemale, B.P. 307, 59020, Lille Cedex, France. 5. Public Health Research Unit (EA2694: Epidemiology and Quality of Care), Lille University, Medical School, Lille, France.
Abstract
PURPOSE: The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting. METHODS: We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters. RESULTS: Three hundred seventy consecutive 153Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases. CONCLUSION: 153Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
PURPOSE: The purpose of this study is to assess the efficacy of 153Sm-EDTMP (Quadramet®) in a clinical setting. METHODS: We have conducted a retrospective study of all consecutive patients (pts) treated with 153Sm-EDTMP for painful bone metastases. At each visit (before and after treatment), four parameters were collected: (i) pain assessment according to the 10-step visual analogue scale (VAS), (ii) sleep disturbance related to pain, (iii) dose of analgesic medication, and (iv) answer to the following closed question "Do you think you obtained a benefit from treatment?" Success of treatment was defined by the combination of these four parameters. RESULTS: Three hundred seventy consecutive 153Sm-EDTMP treatments for painful bone metastases were given. Patients had the following primary tumors: breast carcinoma (153), prostate carcinoma (155), lung carcinoma (27), or other cancers (35). Fifty-eight percent of the patients had received previous external osseous radiotherapy. Ninety-seven percent of the patients were treated with concomitant analgesics and 61% were treated with diphosphonates. A clinical benefit was described in 55.0% of cases at D30. Treatment was more effective in cases of breast and prostate cancers compared with other types of primary cancers. Patients described a benefit at D30 in 62, 58, 6, and 38% of cases of breast, prostate, lung, and other cancers. The subjective efficacy was accompanied by a decrease in analgesic intake in 35.0% of cases. CONCLUSION:153Sm-EDTMP therapy is an effective supportive treatment in patients who suffer from bone metastases, especially in patients with breast or prostate cancer.
Entities:
Keywords:
Bone metastases; Pain palliative; Radiometabolic therapy; Samarium153
Authors: M Tripathi; T Singhal; N Chandrasekhar; P Kumar; C Bal; P K Jhulka; G Bandopadhyaya; A Malhotra Journal: Indian J Cancer Date: 2006 Apr-Jun Impact factor: 1.224
Authors: I Resche; J F Chatal; A Pecking; P Ell; G Duchesne; R Rubens; I Fogelman; S Houston; A Fauser; M Fischer; D Wilkins Journal: Eur J Cancer Date: 1997-09 Impact factor: 9.162
Authors: C Collins; J F Eary; G Donaldson; C Vernon; N E Bush; S Petersdorf; R B Livingston; E E Gordon; C R Chapman; F R Appelbaum Journal: J Nucl Med Date: 1993-11 Impact factor: 10.057
Authors: T Montesano; S Giacomobono; G Acqualagna; M Colandrea; A Di Nicola; L Travascio; M Giancamerla; R D'Apollo; M Toteda; F Ugolini; M Filesi; G Ronga Journal: Clin Ter Date: 2009
Authors: Karen A Autio; Neeta Pandit-Taskar; Jorge A Carrasquillo; Ryan D Stephenson; Susan F Slovin; Dana E Rathkopf; Christina Hong; Glenn Heller; Howard I Scher; Steven M Larson; Michael J Morris Journal: Cancer Date: 2013-06-13 Impact factor: 6.860